Edition:
India

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Capital Market

4.79USD
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
$4.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,649
52-wk High
$37.65
52-wk Low
$2.74

Latest Key Developments (Source: Significant Developments)

Celldex Reports Q4 Loss Per Share of $0.81
Friday, 8 Mar 2019 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2018 RESULTS.Q4 REVENUE $1.8 MILLION VERSUS $3.5 MILLION .Q4 LOSS PER SHARE $0.81.CELLDEX - BELIEVES CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AT DEC 31, 2018, SUFFICIENT TO MEET WORKING CAPITAL REQUIREMENTS, PLANNED OPERATIONS THROUGH 2020.  Full Article

Celldex Therapeutics Reports Q4 Loss Per Share Of $0.81
Friday, 8 Mar 2019 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2018 RESULTS.Q4 LOSS PER SHARE $0.81.Q4 REVENUE $1.8 MILLION VERSUS $12.7 MILLION.CELLDEX - BELIEVES CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AT DEC 31, 2018, SUFFICIENT TO MEET WORKING CAPITAL REQUIREMENTS, PLANNED OPERATIONS THROUGH 2020.  Full Article

Celldex Therapeutics Announces 1 For 15 Reverse Stock Split
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Celldex Therapeutics Inc ::CELLDEX THERAPEUTICS ANNOUNCES REVERSE STOCK SPLIT.ANNOUNCES 1 FOR 15 REVERSE STOCK SPLIT.  Full Article

Celldex Reports Q2 Loss Per Share Of $0.11
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.11.Q2 REVENUE $2.8 MILLION VERSUS I/B/E/S VIEW $2.3 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $114.0 MILLION.  Full Article

Celldex Therapeutics Reports Q1 Loss Per Share $0.84
Thursday, 10 May 2018 

May 10 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.84.Q1 REVENUE $4.1 MILLION VERSUS $1.5 MILLION.Q1 REVENUE VIEW $2.3 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.20 -- THOMSON REUTERS I/B/E/S.CELLDEX - SEES CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AT MAR 31, PROCEEDS FROM SALES OF STOCK SUFFICIENT TO FUND OPERATIONS THROUGH 2020.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $123.2 MILLION VERSUS $139.4 MILLION AS OF DEC 31, 2017.  Full Article

Celldex Therapeutics Approves Workforce Reduction
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Celldex Therapeutics Inc ::CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS.CELLDEX THERAPEUTICS INC - PLANS TO REDUCE ITS 2018 BUDGETED WORKFORCE BY 59 POSITIONS.CELLDEX THERAPEUTICS - REDUCED 2018 BUDGETED WORKFORCE INCLUDES 41 EMPLOYEES TO BE TERMINATED, 18 BUDGETED AND/OR OPEN POSITIONS TO NOT BE FILLED.CELLDEX THERAPEUTICS - EXPECTS TO INCUR RESTRUCTURING CHARGES IN Q2 OF ABOUT $1.3 MILLION RELATED TO CASH SEVERANCE PAYMENTS, OTHER EMPLOYEE-RELATED COSTS.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article